ADGRF3

Across TCGA pan-cancer cohorts, ADGRF3 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of ADGRF3’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ADGRF3 RNA is repressed in tumor relative to normal tissue. In most cancer types ADGRF3 is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

KIRC, KICH, and THCA are the cancer types where ADGRF3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ADGRF3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	−1.845	<.001	12	view →
KICH	Male	All	−2.094	<.001	9	view →
THCA	All	All	−0.352	<.001	7	view →
KIRP	Male	All	−1.619	<.001	6	view →
BRCA	Female	II,III,IV	−0.322	<.001	6	view →
CHOL	All	All	+0.294	<.001	3	view →
PRAD	All	All	−0.217	<.001	2	view →
LIHC	All	All	+0.063	.039	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

ADGRF3–KIRC

Open the KIRC breakdown →